Inosine is a clinically available treatment that increases levels of urate (a natural antioxidant)in the body. Previous studies have suggested that people with higher levels of urate have a reduced risk of developing Parkinson's. These and other observations led to a large Phase III clinical trial of Inosine in Parkinson's (called 'SURE-PD3'). That trial has been ongoing, until this week the study's Data and Safety Monitoring Board - a group of independent experts - reviewed trial progress and available data, and declared that Inosine would be unable to meet the primary end point of the study (which is demonstrating that it can slow Parkinson's progression). The study will now be wound down over the next 6 months giving the opportunity for secondary outcomes to be assessed.

Read more about the trial and a commentary from Michael Schwarzschild, principal investigator at Michael J Fox Foundation and member of CPT's international Linked Clinical Trials committee.